Osiris Therapeutics says commenced steps to terminate enrollment in OTI-15-01 phase III clinical trial
Saturday, October 15, 2016
Osiris Therapeutics Inc says on October 14, 2016, company commenced steps to terminate enrollment in its OTI-15-01 phase III clinical trial.
Osiris -trial was investigating safety and efficacy of OTI-15-01 in patients suffering from chronic DFUS that have not responded to standard of care therapy.
Osiris -patients currently enrolled in trial will continue with their current course of treatment and scheduled visit assessments, as outlined in protocol.
Osiris -decision to terminate reflects co's desire to allocate more of its research, development resources to other clinical programs-SEC filing.
Source : reuters.com
